APA

Morschhauser F., Recher C., Milpied N., Gressin R., Salles G., Brice P., Vey N., Haioun C., Colombat P., Rossi J. F., Deconinck E., Lazreg F., Bergougnoux L., Delsol G. & Attal M. (20130329). A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma. : Annals of oncology : official journal of the European Society for Medical Oncology.

Chicago

Morschhauser F, Recher C, Milpied N, Gressin R, Salles G, Brice P, Vey N, Haioun C, Colombat P, Rossi J F, Deconinck E, Lazreg F, Bergougnoux L, Delsol G and Attal M. 20130329. A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma. : Annals of oncology : official journal of the European Society for Medical Oncology.

Harvard

Morschhauser F., Recher C., Milpied N., Gressin R., Salles G., Brice P., Vey N., Haioun C., Colombat P., Rossi J. F., Deconinck E., Lazreg F., Bergougnoux L., Delsol G. and Attal M. (20130329). A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma. : Annals of oncology : official journal of the European Society for Medical Oncology.

MLA

Morschhauser F, Recher C, Milpied N, Gressin R, Salles G, Brice P, Vey N, Haioun C, Colombat P, Rossi J F, Deconinck E, Lazreg F, Bergougnoux L, Delsol G and Attal M. A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma. : Annals of oncology : official journal of the European Society for Medical Oncology. 20130329.